Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Hammi

- PMLiVE

Novo Nordisk and Vivtex partner in deal worth up to $2.1bn

The companies aim to develop next-generation oral medicines for obesity and diabetes

- PMLiVE

Novo Nordisk and Aspect Biosystems expand collaboration on diabetes research

The companies are working together on cellular medicines to boost, replace or repair biological functions

- PMLiVE

Johnson & Johnson files FDA application for Tremfya in psoriatic arthritis

Approximately 125 million people globally are living with some form of psoriasis

- PMLiVE

Johnson & Johnson’s TAR-200 granted FDA priority review to treat bladder cancer

An estimated 84,870 people will be diagnosed with bladder cancer in the US this year

- PMLiVE

Eli Lilly shares promising phase 3 results for once-weekly insulin candidate efsitora alfa

The company is planning to submit regulatory applications for the candidate by the end of the year

regeneron headquarters

Regeneron gains rights to Hansoh’s GLP-1/GIP receptor agonist in deal worth $2bn

The candidate is being evaluated in a phase 3 obesity trial and phase 2b diabetes study

- PMLiVE

Johnson & Johnson’s Tremfya granted EC approval to treat ulcerative colitis in adults

More than 2.5 million people in Europe are living with the inflammatory bowel disease

- PMLiVE

J&J’s Stelara granted EC approval to treat Crohn’s disease in paediatric patients

Approximately 25% of cases are diagnosed during childhood or adolescence

- PMLiVE

Johnson & Johnson’s Tremfya recommended by CHMP to treat Crohn’s disease

Inflammatory bowel disease is estimated to affect nearly two million people across Europe

- PMLiVE

J&J shares overall survival results for Rybrevant/Lazcluze combination in lung cancer

The regimen was approved by the MHRA earlier this month to treat EGFR-mutated NSCLC

- PMLiVE

Johnson & Johnson to invest more than $55bn in US over next four years

The commitment marks a 25% increase to the company's US investments in the past four years

- PMLiVE

Johnson & Johnson’s Tremfya granted FDA approval to treat Crohn’s disease

An estimated three million people in the US are affected by inflammatory bowel disease

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links